A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.

< Inclusion Criteria>

• Patient of either sex aged 20 to 80 years (both inclusive);
• Patients suffering from Overactive Bladder. based on cardinal symptoms (urgency, nocturia, frequency with or without urge incontinence) for at least 6 months prior to inclusion;
• Patients who document the following symptoms in a 3-day diary card during the 14 day placebo run-in period

• An average of ≥8 micturitions/24 hours;
• Greater than or equal to three incontinence episodes
• A total of ≥3 urgency episodes.

<Exclusion Criteria>

• Patients with Clinically significant bladder outlet obstruction
• Patients with predominant stress incontinence (>2 episode/week)
• Patients with significant urogenital disease such as recurrent urinary tract infection (more than 2/6 months), bladder calculi, interstitial cystitis, urothelial tumours, hysterectomy or prostatectomy in the previous six months;
• Females diagnosed with bladder cancer
• Males diagnosed with bladder cancer
• Patients with obstructive disease of the gastrointestinal tract, intestinal inflammatory disease, severe ulcerative colitis, inflammatory bowel disease, toxic megacolon, intestinal atony or paralytic ileum
• Patients with acute Noehyeolgwangye disease, significant Cardiovascular Disease (arrhythmias, unstable angina pectoris, myocardial infarct, or are using a pacemaker), significant Orthostatic hypotension in the previous six months
• Patients diagnosed with closed angle glaucoma or shallowness of the anterior chamber
• Patients with any contraindication to antimuscarinic drugs